Bio-Rad Laboratories, Inc. (NYSE:BIO) CFO Christine A. Tsingos sold 1,411 shares of the stock in a transaction dated Friday, December 14th. The stock was sold at an average price of $248.00, for a total value of $349,928.00. Following the sale, the chief financial officer now directly owns 6,683 shares in the company, valued at approximately $1,657,384. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Shares of BIO opened at $243.02 on Tuesday. The stock has a market cap of $7.42 billion, a P/E ratio of 47.47, a P/E/G ratio of 3.02 and a beta of 1.09. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.16 and a current ratio of 4.49. Bio-Rad Laboratories, Inc. has a 52-week low of $231.00 and a 52-week high of $345.15.
Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, November 1st. The medical research company reported $0.91 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.25). Bio-Rad Laboratories had a return on equity of 3.72% and a net margin of 55.13%. The company had revenue of $545.10 million for the quarter, compared to analysts’ expectations of $541.23 million. During the same period last year, the company posted $0.91 EPS. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. As a group, research analysts expect that Bio-Rad Laboratories, Inc. will post 5.47 EPS for the current year.
Several large investors have recently added to or reduced their stakes in BIO. Security National Trust Co. purchased a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $125,000. Boussard & Gavaudan Investment Management LLP purchased a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $202,000. First Republic Investment Management Inc. purchased a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $208,000. Regentatlantic Capital LLC purchased a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $222,000. Finally, We Are One Seven LLC purchased a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $254,000. 62.36% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts recently issued reports on the company. Morgan Stanley assumed coverage on Bio-Rad Laboratories in a report on Thursday, September 20th. They set an “equal weight” rating and a $335.00 price objective on the stock. Barclays assumed coverage on Bio-Rad Laboratories in a report on Wednesday, September 5th. They set an “equal weight” rating and a $345.00 price objective on the stock. Goldman Sachs Group assumed coverage on Bio-Rad Laboratories in a report on Wednesday, October 17th. They set a “buy” rating and a $350.00 price objective on the stock. Jefferies Financial Group reissued a “buy” rating and set a $420.00 price objective on shares of Bio-Rad Laboratories in a report on Monday, September 24th. Finally, Zacks Investment Research cut Bio-Rad Laboratories from a “hold” rating to a “strong sell” rating in a report on Monday, November 12th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $338.43.
COPYRIGHT VIOLATION WARNING: “Bio-Rad Laboratories, Inc. (BIO) CFO Christine A. Tsingos Sells 1,411 Shares of Stock” was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2018/12/18/bio-rad-laboratories-inc-bio-cfo-christine-a-tsingos-sells-1411-shares-of-stock.html.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Featured Story: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.